Journal
CELL REPORTS
Volume 18, Issue 2, Pages 324-333Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.12.045
Keywords
-
Categories
Funding
- NIH [R01 AI101400]
- European Union Horizon Research and Innovation Programme under ZIKAlliance Grant [734548]
- Labex Integrative Biology of Emerging Infectious Diseases
- French National Research Agency Investissements d'Avenir'' Program [ANR-10-IHUB-0002, CE14-0029]
Ask authors/readers for more resources
ZIKA virus (ZIKV) is an emerging pathogen responsible for neurological disorders and congenital microcephaly. However, the molecular basis for ZIKV neurotropism remains poorly understood. Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that itmediates ZIKV infection of glial cells. Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells. Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection. During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection. ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428. Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses. Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available